Data availability statement
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
References
1. Sanghai S, Wong C, Wang Z, et al. Rates of Potentially Inappropriate
Dosing of Direct-Acting Oral Anticoagulants and Associations With
Geriatric Conditions Among Older Patients With Atrial Fibrillation: The
SAGE-AF Study. J Am Heart Assoc . Mar 2020;9(6):e014108.
doi:10.1161/JAHA.119.014108
2. Gustafson WL, Saunders J, Vazquez SR, Jones AE, Witt DM. Real-world
study of direct oral anticoagulant dosing patterns in patients with
atrial fibrillation. Pharm Pract (Granada) . 2019 Oct-Dec
2019;17(4):1709.
3. Moudallel S, Steurbaut S, Cornu P, Dupont A. Appropriateness of DOAC
Prescribing Before and During Hospital Admission and Analysis of
Determinants for Inappropriate Prescribing. Front Pharmacol .
2018;9:1220. doi:10.3389/fphar.2018.01220
4. Ezekowitz MD, Spahr J, Ghosh P, Corelli K. Stroke prevention in
atrial fibrillation: established oral anticoagulants versus novel
anticoagulants-translating clinical trial data into practice. J
Interv Card Electrophysiol . Sep 2014;40(3):261-8.
doi:10.1007/s10840-014-9893-z
5. Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW. Evaluation of
dabigatran for appropriateness of use and bleeding events in a community
hospital setting. Am Health Drug Benefits . Oct 2014;7(7):376-84.
6. Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of
prescribing dabigatran etexilate and rivaroxaban in patients with
nonvalvular atrial fibrillation: a prospective study. Ann
Pharmacother . Oct 2014;48(10):1258-68. doi:10.1177/1060028014540868
7. Kucey M, Bolt J, Albers L, Bell A, Iroh N, Toppings J. Prescribing of
Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of
Renal Function Using Standard and Modified Cockcroft-Gault Equations: A
Retrospective Analysis. Can J Hosp Pharm . 2016 Sep-Oct
2016;69(5):409-414.
8. Pattullo CS, Barras M, Tai B, McKean M, Donovan P. New oral
anticoagulants: appropriateness of prescribing in real-world setting.Intern Med J . Jul 2016;46(7):812-8. doi:10.1111/imj.13118
9. Steinberg BA, Shrader P, Thomas L, et al. Off-Label Dosing of
Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The
ORBIT-AF II Registry. J Am Coll Cardiol . Dec
2016;68(24):2597-2604. doi:10.1016/j.jacc.2016.09.966
10. Basaran O, Filiz Basaran N, Cekic EG, et al. PRescriptiOn PattERns
of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER
study). Clin Appl Thromb Hemost . May 2017;23(4):384-391.
doi:10.1177/1076029615614395
11. Howard M, Lipshutz A, Roess B, et al. Identification of risk factors
for inappropriate and suboptimal initiation of direct oral
anticoagulants. J Thromb Thrombolysis . Feb 2017;43(2):149-156.
doi:10.1007/s11239-016-1435-3
12. Shrestha S, Baser O, Kwong WJ. Effect of Renal Function on Dosing of
Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With
Nonvalvular Atrial Fibrillation. Ann Pharmacother . Aug
2017:1060028017728295. doi:10.1177/1060028017728295
13. Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin
EJ. Utilization and prescribing patterns of direct oral anticoagulants.Int J Gen Med . 2017;10:87-94. doi:10.2147/IJGM.S129235
14. Jacobs MS, van Hulst M, Campmans Z, Tieleman RG. Inappropriate
non-vitamin K antagonist oral anticoagulants prescriptions: be cautious
with dose reductions. Neth Heart J . Jul 2019;27(7-8):371-377.
doi:10.1007/s12471-019-1267-9
15. Yu HT, Yang PS, Kim TH, et al. Impact of Renal Function on Outcomes
With Edoxaban in Real-World Patients With Atrial Fibrillation.Stroke . 10 2018;49(10):2421-2429.
doi:10.1161/STROKEAHA.118.021387
16. Shum P, Klammer G, Toews D, Barry A. Anticoagulant Utilization and
Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular
Atrial Fibrillation. Can J Hosp Pharm . 2019 Nov-Dec
2019;72(6):428-434.
17. Jang BM, Lee OS, Shin EJ, et al. Factors related to inappropriate
edoxaban use. J Clin Pharm Ther . Oct 2019;44(5):760-767.
doi:10.1111/jcpt.12999
18. Angel Y, Zeltser D, Berliner S, et al. Hospitalization as an
opportunity to correct errors in anticoagulant treatment in patients
with atrial fibrillation. Br J Clin Pharmacol . 12
2019;85(12):2838-2847. doi:10.1111/bcp.14116
19. Antoniazzi S, Ardoino I, Proietti M, et al. Appropriateness of
prescription of oral anticoagulant therapy in acutely hospitalized older
people with atrial fibrillation. Secondary analysis of the SIM-AF
cluster randomized clinical trial. Br J Clin Pharmacol . 09
2019;85(9):2134-2142. doi:10.1111/bcp.14029
20. Quintens C, De Rijdt T, Van Nieuwenhuyse T, et al. Development and
implementation of ”Check of Medication Appropriateness” (CMA): advanced
pharmacotherapy-related clinical rules to support medication
surveillance. BMC Med Inform Decis Mak . 02 2019;19(1):29.
doi:10.1186/s12911-019-0748-5
21. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining
Anticoagulation Clinics in the Era of Direct Oral Anticoagulants.Circ Cardiovasc Qual Outcomes . Mar 2016;9(2):182-5.
doi:10.1161/CIRCOUTCOMES.115.002366
22. Uppuluri EM, McComb MN, Shapiro NL. Implementation of a Direct Oral
Anticoagulation Screening Service at a Large Academic Medical Center
Provided by a Pharmacist-managed Antithrombosis Clinic as a Method to
Expand Antithrombotic Stewardship Efforts. J Pharm Pract . Jun
2020;33(3):271-275. doi:10.1177/0897190018799200
23. Boswell R, Bungard TJ. More than Just Chasing INRs: Patient-Centred
Care in an Anticoagulation Clinic. Can J Hosp Pharm . 2015 May-Jun
2015;68(3):254-7. doi:10.4212/cjhp.v68i3.1460
24. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the
efficacy and safety of new oral anticoagulants with warfarin in patients
with atrial fibrillation: a meta-analysis of randomised trials.Lancet . Mar 2014;383(9921):955-62.
doi:10.1016/S0140-6736(13)62343-0
25. Cools F, Wollaert B, Vervoort G, et al. Treatment patterns in
anticoagulant therapy in patients with newly diagnosed atrial
fibrillation in Belgium: results from the GARFIELD-AF registry.Acta Cardiol . Aug 2019;74(4):309-318.
doi:10.1080/00015385.2018.1494089
26. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA.
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With
Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol . Jun
2017;69(23):2779-2790. doi:10.1016/j.jacc.2017.03.600
27. Bendayan M, Mardigyan V, Williamson D, et al. Muscle Mass and Direct
Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation.J Am Geriatr Soc . Jan 2021;doi:10.1111/jgs.16992
28. Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral
Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.Stroke . 12 2018;49(12):2933-2944.
doi:10.1161/STROKEAHA.118.020232
29. Chan YH, Lee HF, See LC, et al. Effectiveness and Safety of Four
Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial
Fibrillation. Chest . 09 2019;156(3):529-543.
doi:10.1016/j.chest.2019.04.108
30. Van Ganse E, Danchin N, Mahé I, et al. Comparative Safety and
Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation:
The NAXOS Study. Stroke . Jul 2020;51(7):2066-2075.
doi:10.1161/STROKEAHA.120.028825
31. Grymonprez M, Steurbaut S, De Backer TL, Petrovic M, Lahousse L.
Effectiveness and Safety of Oral Anticoagulants in Older Patients With
Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front
Pharmacol . 2020;11:583311. doi:10.3389/fphar.2020.583311
32. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management,
and outcome of rivaroxaban bleeding in daily care: results from the
Dresden NOAC registry. Blood . Aug 2014;124(6):955-62.
doi:10.1182/blood-2014-03-563577
33. Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral
anticoagulant use in patients with renal impairment. Ther Adv
Cardiovasc Dis . Sep 2017;11(9):243-256. doi:10.1177/1753944717714921
34. Miyazaki M, Matsuo K, Uchiyama M, et al. Inappropriate direct oral
anticoagulant dosing in atrial fibrillation patients is associated with
prescriptions for outpatients rather than inpatients: a single-center
retrospective cohort study. J Pharm Health Care Sci . 2020;6:2.
doi:10.1186/s40780-020-0157-z
35. Yoshikawa A, Ramirez G, Smith ML, et al. Opioid Use and the Risk of
Falls, Fall Injuries and Fractures among Older Adults: A Systematic
Review and Meta-Analysis. J Gerontol A Biol Sci Med Sci . Feb
2020;doi:10.1093/gerona/glaa038
36. Seppala LJ, van de Glind EMM, Daams JG, et al. Fall-Risk-Increasing
Drugs: A Systematic Review and Meta-analysis: III. Others. J Am
Med Dir Assoc . 04 2018;19(4):372.e1-372.e8.
doi:10.1016/j.jamda.2017.12.099
37. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and
emerging oral anticoagulants. Int J Clin Pract . Jun
2010;64(7):956-67. doi:10.1111/j.1742-1241.2009.02286.x
38. Ashjian E, Kurtz B, Renner E, Yeshe R, Barnes GD. Evaluation of a
pharmacist-led outpatient direct oral anticoagulant service. Am J
Health Syst Pharm . Apr 2017;74(7):483-489. doi:10.2146/ajhp151026
39. Hendriks JM, de Wit R, Crijns HJ, et al. Nurse-led care vs. usual
care for patients with atrial fibrillation: results of a randomized
trial of integrated chronic care vs. routine clinical care in ambulatory
patients with atrial fibrillation. Eur Heart J . Nov
2012;33(21):2692-9. doi:10.1093/eurheartj/ehs071
40. Kovacs RJ, Flaker GC, Saxonhouse SJ, et al. Practical management of
anticoagulation in patients with atrial fibrillation. J Am Coll
Cardiol . Apr 2015;65(13):1340-1360. doi:10.1016/j.jacc.2015.01.049
41. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart
Rhythm Association Practical Guide on the use of non-vitamin K
antagonist oral anticoagulants in patients with atrial fibrillation:
executive summary. Europace . 08 2018;20(8):1231-1242.
doi:10.1093/europace/euy054
42. Dreijer AR, Kruip MJHA, Diepstraten J, et al. Effect of
antithrombotic stewardship on the efficacy and safety of antithrombotic
therapy during and after hospitalization. PLoS One .
2020;15(6):e0235048. doi:10.1371/journal.pone.0235048